MammoWave has been awarded the H2020 EU
funding SMEINST Phase II grant
MammoWave clinical trials are in progress at Perugia Hospital “Azienda Ospedaliera S. Maria della Misericordia”, Italy, and at Foligno Hospital, Italy. MammoWave use for clinical trials was authorized by Italian Ministry of Health and by the Ethical Committee of Regione Umbria, Italy. The MD clinical trials promoter is Dr. Michele Duranti, director of the Department of Diagnostic Imaging at Perugia Hospital, S. Maria della Misericordia. The MD clinical trials responsible at Foligno Hospital is Dr. Riccardo Loretoni, director of the Breast Unit. Clinical trials results obtained up to now show the capability of MammoWave to detect breast lesions (including carcinoma, fibroadenoma, and microcalcifications). Results have been published in "Biomedical Signal Processing and Control – Journal – Elsevier" and in "Measurement - Journal – Elsevier". MammoWave performance in detecting breast lesions can be enhanced through AI-Artificial Intelligence, as reported in "Scientific Reports- Journal – Nature". Thanks to the H2020 SMEINST Phase II funding, UBT is now enrolling patients in further four Hospitals, including Humanitas, Milano and San Martino, Genova, in Italy; Universitätsklinikum di Erlangen in Germany e Hospital Virgen de la Salud in Toledo, Spain.
Why MammoWave technology is unique
News & Events
Keep in touch
Sign up for our newsletter to get updates about UBT and our results.